Sign inCreate account

Report workspace tools

NCT05312697TERMINATEDanonymous

A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Sponsor

Source record

Ultragenyx Pharmaceutical Inc

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Setrusumab

Indication / condition

AI-normalized

Osteogenesis Imperfecta

Intervention

Source record

Setrusumab

Source & freshness

Source record

NCT ID

NCT05312697

Original source

ClinicalTrials.gov

Source last updated

Jul 23, 2025

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05312697

Title

A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Sponsor

Ultragenyx Pharmaceutical Inc

Status

TERMINATED

Phase

PHASE2

Condition raw

Osteogenesis Imperfecta

Condition normalized

Osteogenesis Imperfecta

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Setrusumab

Target normalized

Setrusumab

Interventions

Setrusumab

Public preview

Source record

The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05312697

Status

TERMINATED

Phase

PHASE2

Sponsor

Ultragenyx Pharmaceutical Inc

Executive brief

Investment-Ready Snapshot

The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 23, 2025
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05312697

Indication

Osteogenesis Imperfecta

Modality

monoclonal antibody

Target

Setrusumab

Intervention

Setrusumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.